# OnCo record setmelanotide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/setmelanotide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "setmelanotide" ;
  schema:name "Setmelanotide"@en ;
  schema:alternateName "RM-493"@en, "Imcivree" ;
  schema:description "Setmelanotide is a daily injection that switches back on the brain's fullness signal. It is approved for rare genetic causes of obesity and, since March 2026 in the United States, for the continuous weight gain that follows damage to the hypothalamus from a tumour such as craniopharyngioma or from its treatment."@en ;
  schema:url <https://onco.cc/drugs/setmelanotide/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Setmelanotide> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2512275>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9>, <https://en.wikipedia.org/wiki/Setmelanotide> ;
  onco:status "approved" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Subcutaneous melanocortin-4 receptor agonist" ;
  onco:approval "US 2020: Chronic weight management in obesity due to POMC, PCSK1 or LEPR deficiency", "US 2026: Acquired hypothalamic obesity in adults and children aged 4 years and older" ;
  onco:cancers <https://onco.cc/cancers/craniopharyngioma/> ;
  onco:companies <https://onco.cc/companies/rhythm-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/transcend/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/> .